EPHA2 and neoplasm: The combination of EPHA2-targeting siRNA-DOPC with paclitaxel, on the other hand, resulted in a drastic reduction of tumor growth in vivo in comparison with treatment with paclitaxel and a nonsilencing siRNA [79], while platinum triggered an oncogenic EPHA2-S897 phosphorylation in vivo associated with platinum resistance [80].